Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,348.04 85.48 0.53%
S&P 500 1,849.82 6.84 0.37%
NASDAQ 4,052.65 18.49 0.46%
Ticker Volume Price Price Delta
STOXX 50 3,123.37 31.85 1.03%
FTSE 100 6,569.08 27.47 0.42%
DAX 9,264.69 90.98 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

The Zacks Analyst Blog Highlights: LinkedIn, AOL, Facebook, Paychex and Qiagen



The Zacks Analyst Blog Highlights: LinkedIn, AOL, Facebook, Paychex and Qiagen

PR Newswire

CHICAGO, May 1, 2013

CHICAGO, May 1, 2013 /PRNewswire/ -- Zacks.com announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include LinkedIn Corporation (NYSE:LNKD),
AOL Inc. (NYSE:AOL), Facebook Inc. (Nasdaq:FB), Paychex Inc. (Nasdaq:PAYX) and
Qiagen (Nasdaq:QGEN).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Get the most recent insight from Zacks Equity Research with the free Profit
from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Tuesday's Analyst Blog:

LinkedIn Likely to Post Positive Surprise

We expect professional networking solution provider LinkedIn Corporation
(NYSE:LNKD) to beat expectations when it reports third-quarter 2013 results on
May 2.

Why a Likely Positive Surprise?

Our proven model shows that LinkedIn is likely to beat the earnings estimate
because it has the right combination of two key ingredients.

Zacks ESP: Expected Surprise Prediction or ESP (Zacks Earnings ESP: A Better
Method), which represents the difference between the Most Accurate Estimate
and the Zacks Consensus Estimate is at +120.0%. This is very meaningful and a
leading indicator of a likely positive earnings surprise for shares.

Zacks Rank #2 (Buy): LinkedIn carries a Zacks Rank #2 (Buy). Note that stocks
with Zacks Ranks of #1, #2 and #3 have a significantly higher chance of
beating estimates. The sell rated stocks (#4 and #5) should never be
considered going into an earnings announcement. 

The combination of LinkedIn's Zacks Rank #2 (Buy) and +120% ESP makes us very
confident in looking for an earnings beat on May 2.

What is Driving the Better than Expected Earnings?

The company has been delivering good numbers over the last few quarters,
driven by the increase in demand for their professional networking solutions,
which provides added benefits to prospective employers and talent acquisition
firms searching for skilled manpower. As a result, the Talent Solutions and
Premium Subscription segments were have strengthened over the last few
quarters. Moreover, the purchase of Pulse greatly improves its marketing
efforts in the Talent Solutions business.

Other Stocks to Consider

LinkedIn is not the only firm looking up this earnings season. We also see
likely earnings beats coming from these 3 industry peers:

AOL Inc. (NYSE:AOL), Earnings ESP of +3.03% and Zacks Rank #2 (Buy)

Facebook Inc. (Nasdaq:FB), Earnings ESP of +12.50%and Zacks Rank #2 (Buy)

Paychex Inc. (Nasdaq:PAYX), Earnings ESP of +2.70% and Zacks Rank #2 (Buy)

Qiagen Acquires Ingenuity Systems

In an attempt to manage its growing volume of genomic data, Qiagen
(Nasdaq:QGEN) recently acquired Calif.-based privately owned company,
Ingenuity Systems, Inc. Through the acquisition, Qiagen will have access to
Ingenuity's proprietary Ingenuity Knowledge Base and software applications,
which is an advanced knowledge system and analysis solution for complex
biomedical information. However, financial terms of the deal were not
disclosed.

Over the recent past volume of data generation through next-generation
sequencing (NGS) has been increasing. This has compelled Qiagen to realize the
need for advanced solutions of Ingenuity. These solutions, according to the
company, will act as a critical success factor in analysis and interpretation
of complex biological data.

Qiagen claims that, with the Ingenuity products, the company will be able to
widen its scope in the rapidly growing market of sequencing with faster and
efficient data analysis. Ingenuity stated that, while an entire human genome
sequence takes only 2 days to complete, the data analysis can take months and
years. However, the Ingenuity product line needs some time (may be some
minutes) for data interpretation.

Viewing the substantial potential of the molecular diagnostic market globally,
Qiagen is currently focusing on expanding its diagnostics products offering.
The company currently derives around 50% of its total revenue from this
segment, which is likely to increase with this acquisition. Qiagen has
acquired several companies to expand its product portfolio, the significant
ones are Cellestis and Ipsogen in 2011.

We are encouraged by Qiagen's focus on strategic initiatives to drive growth
and profitability in the molecular diagnostics market. Its innovative tests in
the genomic/esoteric arena, with a focus on the high-margin esoteric testing
business, are expected to accelerate the company's sales growth on the back of
growing market demand, not only domestic but worldwide.

This is also provoking several small laboratory companies to introduce their
comprehensive portfolio of genetic tests.

Want more from Zacks Equity Research? Subscribe to the free Profit from the
Pros newsletter: http://at.zacks.com/?id=5515.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
today: http://at.zacks.com/?id=5517

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of
Profitable ideas GUARANTEED to be worth your time! Register for your free
subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance
numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook:
http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

SOURCE Zacks Investment Research, Inc.

Website: http://www.zacks.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement